ONMD (ONMD)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from ONMD's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from ONMD's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $1M | $1M | $643,000 | $1M |
| Net income | -$30M | -$34M | -$10M | -$3M |
| Free cash flow | -$5M | -$5M | -$7M | -$8M |
| EPS (diluted) | -$7.66 | -$4.65 | -$0.36 | -$0.06 |
| Operating margin | -669.1% | -671.2% | -1493.8% | -711.3% |
Where the revenue comes from
Revenue by products, fiscal 2025. Every breakdown, year by year.
Superinvestors who own ONMD
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by ONMD's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Sep 10, 2026 | Jeffrey Yu Chief Medical Officer |
142,857 | $0.63 | $90,000 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when ONMD trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are ONMD insiders buying the stock?
1 open-market insider purchase of ONMD in the last 12 months, from SEC Form 4 filings.
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.